For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of SELLAS Life Sciences Group Inc (NASDAQ: SLS) was $4.11 for the day, up 18.79% from the previous closing price of $3.46. In other words, the price has increased by $18.79 from its previous closing price. On the day, 16.53 million shares were traded. SLS stock price reached its highest trading level at $4.3268 during the session, while it also had its lowest trading level at $3.34.
Ratios:
Our analysis of SLS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.28 and its Current Ratio is at 8.28. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on July 21, 2021, initiated with a Overweight rating and assigned the stock a target price of $18.
On April 02, 2018, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11.H.C. Wainwright initiated its Buy rating on April 02, 2018, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 19 ’25 when Kalin Katherine Bach bought 63,400 shares for $1.59 per share. The transaction valued at 100,806 led to the insider holds 104,400 shares of the business.
VAN NOSTRAND ROBERT L bought 10,000 shares of SLS for $14,800 on Jun 12 ’25. The Director now owns 20,400 shares after completing the transaction at $1.48 per share. On May 30 ’25, another insider, Wasman Jane, who serves as the Director of the company, bought 20,000 shares for $1.69 each. As a result, the insider paid 33,800 and bolstered with 30,400 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLS now has a Market Capitalization of 699859200 and an Enterprise Value of 541716608.
Stock Price History:
The Beta on a monthly basis for SLS is 2.27, which has changed by 2.7204301 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, SLS has reached a high of $5.18, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 83.17%, while the 200-Day Moving Average is calculated to be 124.71%.
Shares Statistics:
SLS traded an average of 7.53M shares per day over the past three months and 19670580 shares per day over the past ten days. A total of 142.44M shares are outstanding, with a floating share count of 141.07M. Insiders hold about 0.97% of the company’s shares, while institutions hold 23.72% stake in the company. Shares short for SLS as of 1767139200 were 49429420 with a Short Ratio of 6.57, compared to 1764288000 on 33260681. Therefore, it implies a Short% of Shares Outstanding of 49429420 and a Short% of Float of 34.96.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of SELLAS Life Sciences Group Inc (SLS).The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.05 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.24 and -$0.29 for the fiscal current year, implying an average EPS of -$0.26. EPS for the following year is -$0.32, with 3.0 analysts recommending between -$0.2 and -$0.38.
